• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Procrit (epoetin alfa) Dec 2004

Audience: Oncologists, hematologists and other healthcare professionals

Ortho Biotech Products notified healthcare professionals of important changes to the safety information and dosing sections of the product labeling for Procrit. To ensure consistency with labeling for other products in this class, changes to hemoglobin rate of rise and target were made. The new prescribing information recommends that the target hemoglobin in patients with cancer should not exceed 12 grams per deciliter in men and women.

[August 13, 2004 - Letter - Ortho Biotech]